Indication

Conditioning prior to allogeneic hematopoietic stem cell transplant

Conditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity. Read more about Conditioning prior to allogeneic hematopoietic stem cell transplant

32 drugs 29 manufacturers

Advertisement

Drugs that treat it

Common Conditioning prior to allogeneic hematopoietic stem cell transplant therapies.

Showing 1–9 of 32 drugs

MYLERAN (busulfan)

CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT·+1
GSK

MYLERAN (busulfan)

CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT·+1
PRASCO LABS

BUSULFEX (busulfan)

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
Otsuka Pharmaceutical Co., Ltd.

BUSULFEX (busulfan)

CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
OTSUKA AMERICA

THIOTEPA

CARCINOMA OF BREAST·+6
WEST-WARD,INC.

MYLERAN (busulfan)

CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT·+1
ASPEN/PRASCO LA

BUSULFAN

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
American Regent

BUSULFAN

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
SAGENT PHARMACE
Filter & compare in the drug finder →Opens the drug finder with Conditioning prior to allogeneic hematopoietic stem cell transplant preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Conditioning prior to allogeneic hematopoietic stem cell transplant.

Conditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity.

Administered to pediatric or adult patients with hematologic malignancies, marrow failure syndromes, or congenital immunodeficiencies, this clinical state involves intensive pre-transplant cytoreduction and immunosuppression.

Pathophysiologically, the regimen—delivered via myeloablative, reduced-intensity, or non-myeloablative intensities—targets the host hematopoietic and immune systems through profound myelodepletion and lymphodepletion.

This eliminates residual diseased cells, empties marrow stem cell niches, and suppresses recipient immune responses to prevent graft rejection and permit successful donor cell engraftment.

Personalize your experience

Follow Conditioning prior to allogeneic hematopoietic stem cell transplant and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it